These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38726357)

  • 1. Correction: Expert Opinions on the Management of Hemophilia A in India: The Role of Emicizumab.
    Gupta N; Dutta A; Ahmed B; Ross CR; S C; Dolan G; John MJ; Radhakrishnan N; Aggarwal S; Seth T; Kaul V; Shah V
    Cureus; 2024 May; 16(5):c172. PubMed ID: 38726357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emicizumab for the prevention of bleeds in hemophilia A.
    Mahlangu J
    Expert Opin Biol Ther; 2019 Aug; 19(8):753-761. PubMed ID: 31150297
    [No Abstract]   [Full Text] [Related]  

  • 3. Key questions in the new hemophilia era: update on concomitant use of FVIII and emicizumab in hemophilia A patients with inhibitors.
    Carcao M; Mancuso ME; Young G; Jiménez-Yuste V
    Expert Rev Hematol; 2021 Feb; 14(2):143-148. PubMed ID: 33499681
    [No Abstract]   [Full Text] [Related]  

  • 4. Management of surgery in persons with hemophilia A receiving emicizumab prophylaxis: data from a national hemophilia treatment center.
    Cohen O; Levy-Mendelovich S; Budnik I; Ludan N; Lyskov SK; Livnat T; Avishai E; Efros O; Lubetsky A; Lalezari S; Misgav M; Brutman-Barazani T; Kenet G; Barg AA
    Res Pract Thromb Haemost; 2023 Aug; 7(6):102178. PubMed ID: 37876894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacology of emicizumab for the treatment of hemophilia A.
    Yoneyama K; Schmitt C; Portron A; Kiialainen A; Kotani N; Jaminion F; Retout S; Adamkewicz JI
    Expert Rev Clin Pharmacol; 2023; 16(9):775-790. PubMed ID: 37529848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness study of prophylaxis with emicizumab versus bypassing agents in patients with severe hemophilia A in Peru.
    Bitrán R; Peña C; Arpón P; Loayza N; Salas K; Del Villar C; Chumpitaz G; Salinas V
    Medwave; 2022 Mar; 22(2):e8703. PubMed ID: 35323824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expert opinion paper on the treatment of hemophilia a with emicizumab.
    López-Jaime FJ; Benítez O; Díaz Jordán BL; Montaño A; Coll J; Quintana París L; Gómez-Del Castillo Solano MDC
    Hematology; 2023 Dec; 28(1):2166334. PubMed ID: 36636993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamics Monitoring of Emicizumab in Patients with Hemophilia A.
    Bertaggia Calderara D; Marchi Cappelletti R; Batista Mesquita Sauvage AP; Durual S; Gomez FJ; Zermatten MG; Aliotta A; Casini A; Alberio L
    Thromb Haemost; 2023 Oct; 123(10):955-965. PubMed ID: 37336473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantification of emicizumab by mass spectrometry in plasma of people with hemophilia A: A method validation study.
    Donners AAMT; Gerencsér L; van der Elst KCM; Egberts TCG; de Maat MPM; Huisman A; Urbanus RT; El Amrani M
    Res Pract Thromb Haemost; 2022 May; 6(4):e12725. PubMed ID: 35702589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costs of the management of hemophilia A with inhibitors in Spain.
    Bonanad S; Álvarez MT; Núñez R; Poveda JL; Gil B; Ruíz-Beato E; Durán A; Ivanova Y; Pérez-Román I; González-Domínguez A
    Glob Reg Health Technol Assess; 2021; 8():35-42. PubMed ID: 36627877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serious bleeds in pediatric persons with hemophilia A on emicizumab prophylaxis.
    Garcia J; Hammer MR; Zia A
    Res Pract Thromb Haemost; 2023 Nov; 7(8):102238. PubMed ID: 38053983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emicizumab: a novel drug in hemophilia A prophylaxis - a narrative review.
    Mazurkiewicz Ł; Czernikiewicz K; Rupa-Matysek J; Gil L
    Expert Rev Hematol; 2022 Oct; 15(10):933-942. PubMed ID: 36191306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose emicizumab prophylaxis in patients with severe hemophilia A: a retrospective study bringing new hope for our patients.
    Patil R; Shanmukhaiah C; Gogtay NJ; Pandey P; Patil K; Jijina F; Madkaikar M
    J Thromb Haemost; 2024 Apr; 22(4):1024-1030. PubMed ID: 38160726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the safety of emicizumab in patients with hemophilia A.
    Langer AL; Etra A; Aledort L
    Expert Opin Drug Saf; 2018 Dec; 17(12):1233-1237. PubMed ID: 30462521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Surgery in patients with severe or inhibitory hemophilia A under prevention injection of emicizumab].
    Shutov SA; Zozulya NI; Novikov VA; Shutova NA; Glebova AI; Kitsenko EA
    Khirurgiia (Mosk); 2023; (5):72-83. PubMed ID: 37186654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emicizumab for hemophilia A without inhibitors.
    Cafuir L; Kruse-Jarres R; Mancuso ME; Kempton CL
    Expert Rev Hematol; 2019 Jul; 12(7):515-524. PubMed ID: 31130012
    [No Abstract]   [Full Text] [Related]  

  • 17. Correction: An Open-Label, Single-Arm, Multicenter, Observational Study Evaluating the Safety and Effectiveness of Akynzeo® in the Management of Chemotherapy-Induced Nausea and Vomiting in India.
    Mv C; Thomas B; Biswas G; Gupta S; Dattatreya PS; Bhagat S; Patil S; Bhushan S; Barkate H
    Cureus; 2024 Apr; 16(4):c169. PubMed ID: 38651087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Emicizumab: a paradigm shift in hemophilia treatment].
    Nogami K
    Rinsho Ketsueki; 2020; 61(5):536-541. PubMed ID: 32507821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic emicizumab for hemophilia A in the Asia-Pacific region: A randomized study (HAVEN 5).
    Yang R; Wang S; Wang X; Sun J; Chuansumrit A; Zhou J; Schmitt C; Hsu W; Xu J; Li L; Chang T; Zhao X
    Res Pract Thromb Haemost; 2022 Feb; 6(2):e12670. PubMed ID: 35284778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Budget Impact of Emicizumab for Routine Prophylaxis of Bleeding Episodes in Patients With Hemophilia A With Inhibitors.
    Watanabe AH; Lee SWH; Chai-Adisaksopha C; Lim MY; Chaiyakunapruk N
    Value Health Reg Issues; 2022 Mar; 28():7-13. PubMed ID: 34800834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.